Skip to main content
PMC home page
Basic and Clinical Andrology logoLink to Basic and Clinical Andrology
. 2020 Dec 9;30:19. doi: 10.1186/s12610-020-00117-1

Idiopathic central precocious puberty in a Klinefelter patient: highlights on gonadotropin levels and pathophysiology

Salwan Maqdasy 1,2,3,✉, Bertrand Barres 4, Gaelle Salaun 5, Marie Batisse-Lignier 1, Celine Pebrel-Richard 5, Kelvin H M Kwok 6, André Labbé 7, Philippe Touraine 8, Florence Brugnon 2,9,10, Igor Tauveron 1,2,3
PMCID: PMC7724694  PMID: 33292161

Abstract

Background

Idiopathic central precocious puberty (ICPP) is supposed to be non-existent in a context of testicular destruction that is typically present in Klinefelter syndrome (KS). Herein, we describe a rare case of ICPP in a Klinefelter patient (47,XXY) with 2 maternal X chromosomes. Moreover, we highlight the differences in gonadotropin levels in comparison to males with ICPP and a normal karyotype.

Case presentation

An 8 years old boy with a history of cryptorchidism was evaluated for precocious puberty (Tanner staging: P2/G3). Both testes measured 25x35mm. His hormonal profile confirmed a central origin of precocious puberty with high serum testosterone (4.3 ng/ml), luteinizing hormone [LH (3.5 UI/l)] and follicle stimulating hormone [FSH (7.7 UI/l)] levels. Luteinizing hormone-releasing hormone (LHRH) test amplified LH and FSH secretion to 24 and 14 UI/l respectively. Brain magnetic resonance imaging (MRI) was normal. No MKRN3 mutation was detected. He was treated for ICPP for two years. During puberty, he suffered from hypergonadotropic hypogonadism leading to the diagnosis of KS (47,XXY karyotype). Chromosomal analysis by fluorescent multiplex polymerase chain reaction (PCR) using X chromosome microsatellite markers identified 2 maternal X chromosomes.

Analysing 8 cases of KS developing ICPP (our reported case and 7 other published cases) revealed that these KS patients with ICPP have higher LH and FSH levels during ICPP episode than in ICPP patients with a normal karyotype (ICPP with KS vs ICPP with a normal karyotype: LH levels 9.4 ± 12 vs 1.1 ± 0.6 UI/l; FSH levels 23.1 ± 38.5 vs 2.7 ± 1.5 UI/l). Furthermore, their response to gonadotropin-releasing hormone (GnRH) stimulation is characterized by excessive LH and FSH secretion (LH levels post-GnRH: 58 ± 48 vs 15.5 ± 0.8 UI/l; FSH levels post-GnRH: 49.1 ± 62.1 vs 5.7 ± 3.9 UI/l).

Conclusions

ICPP in boys is extremely rare. The pathophysiology of ICPP in KS is unknown. However, maternal X supplementary chromosome and early testicular destruction may play a significant role in the initiation of ICPP, in part explaining the relative “overrepresentation of ICPP in KS. Thus, karyotype analysis could be considered for boys suffering from ICPP, especially if testicular size is smaller or gonadotropins are significantly elevated.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12610-020-00117-1.

Keywords: Precocious puberty, Idiopathic, Klinefelter, Gonadotropin

Background

Puberty in boys is initiated when gonadotropin-releasing hormone (GnRH) secretion is amplified, inducing the secretion of gonadotropins. Pulsatile secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) is accompanied by enlarged testicular volume, testosterone secretion and initiation of spermatogenesis [1]. The age of puberty initiation is variable across sex, ethnicity, and is influenced by genetic and nutritional factors. Precocious puberty (PP) is generally due to premature sexual steroid secretion [1–4]. In most cases, puberty is considered precocious in boys if it is initiated before 9 years old. The prevalence of PP is about 1 to 8/10000 with a female/male ratio of 9/1. Central precocious puberty (CPP) is caused by earlier pulsatile secretion of GnRH and gonadotropins [2]. Unlike delayed puberty, CPP remains idiopathic in most of the cases (ICPP) [4]. Many observations suggest a possible link between chromosomal anomalies and PP, especially in Klinefelter syndrome (KS) [5–7]. KS is the most frequent dysgonosomia in boys that leads to incomplete puberty and hypergonadotropic hypogonadism [8]. Indeed, most cases of PP in KS arise from germ cell tumors secreting human chorionic gonadotropin (hCG). While many cases of ICPP in KS have been reported in the literature, [9–14], the physiopathology remains unclear. Furthermore, the hormonal profile of patients with ICPP and KS is not well characterized. The study of patients with divergent problems such as ICPP and KS might improve the understanding of ICPP pathophysiology and point out factors that influence the timing of puberty initiation.

We describe a case of ICPP in a boy who, a few years later, developed hypogonadism in his adulthood secondary to KS (with 2 maternal X chromosomes). In addition to our patient, we analyze 7 other cases of ICPP in KS patients previously reported in the literature. Among patients with ICPP, those who are also suffering from KS have higher levels of gonadotropins and an exaggerated response to GnRH stimulation compared to those with a normal karyotype. This comparison highlights the possibility of a primitive testicular factor, such as precocious germ cell and Leydig cell dysfunction, participating in the induction of ICPP in KS.

Case presentation

A boy, born in 1994, was evaluated for suspicion of precocious puberty. At 8 years old, his height (150 cm) exceeded the mean for age by 3 standard deviations with a growth rate of 10 cm per year. He developed puberty signs (Tanner staging: P2/G3). Both testes measured 25x35mm, the penis was enlarged and increased in length. Bone age was advanced (10 years according to modified Sempé’s method). His past history was marked by cryptorchidism, operated at age of 1 year. No facial dysmorphia, behavioural abnormalities or mental retardation were noticed.

His hormonal profile confirmed a central origin of precocious puberty with high serum testosterone (4.3 ng/ml) for age, and detectable LH (3.5 UI/l) and FSH (7.7 UI/l) (adult male reference values for FSH: 1.1–9.9 UI/l, and LH: 0.9–6.6 UI/l).

Luteinizing hormone-releasing hormone (LHRH) test amplified LH and FSH secretion to 24 and 14 UI/l respectively (Table 1). Hypothalamic-pituitary MRI was normal. Due to advanced bone age and growth acceleration, he was treated with triptoreline (3 mg, intramuscular injection every 28 days). Under this treatment, LH, FSH and testosterone were attenuated to a prepubertal level (0.2 UI/l, 0.4 UI/l and 0.2 ng/ml respectively) (Table 1). In 2005, the treatment was stopped, and puberty resumed. At age of 20, he consulted for hypogonadism and bilateral gynecomastia. His definitive height was 178 cm (predicted height was 173 cm, with mid-parental height estimated to 166 cm) and his weight was 86 kg (+ 1 SD). The testicular size was reduced (25 × 12 mm). Further evaluation confirmed azoospermia, and low testosterone levels (1.16 ng/ml, reference values for adults > 2.75 ng/ml) with hypergonadotropic hypogonadism (LH and FSH increased to 26 and 40 UI/l respectively) (Table 1). Testicular biopsy revealed a hyalinized tissue with failed spermatozoa retrieval.

Table 1.

Clinical and biological parameters of the patient during and after puberty

Age 8 years 9.5 years 9 years,
10 months 		10 years,
4 months 		11.5 years 20 years
LH (UI/l) 3.5 0.2 0.2 0.2 0.3 26
FSH (UI/l) 7.7 0.4 0.4 0.4 0.5 39.6
Testosterone (ng/ml) 4.35 0.3 0.2 0.2 0.3 1.16
Testicular diameter (mm) 35 × 25 35 × 20 35 × 20 35 × 20 35 × 20 25 × 12
Tanner staging P2G3 P2G3 P2G3 P2G3 P3G3 P3G2
Bone age 9 years, 11 months 11 years, 6 months 11 years, 6 months 12 years, 3 months
Open in a new tab

LH: luteinizing hormone; FSH: follicle stimulating hormone; UI: International units

Period of Triptoreline treatment. Reference values: FSH: 1.1–9.9 UI/l, LH: 0.9–6.6 UI/l

Chromosome analysis was performed on GTG-banded and RHG-banded metaphases prepared from cultured peripheral blood according to the standard protocols.

The origin of the supernumerary X chromosome was investigated by fluorescent multiplex polymerase chain reaction (PCR) to study short tandem repeats polymorphisms (supplementary methods).

Peripheral blood cytogenetic analysis of our patient revealed 47 chromosomes, with an extra X chromosome in all analyzed metaphases, confirming KS. Array-comparative genomic hybridization (CGH) excluded the presence of any other genomic imbalance, except for copy number variations (CNV) previously described in the normal population according to the Database of Genomic Variants (http://projects.tcag.ca/variation). Microsatellite analysis in X chromosome showed two X chromosomes of maternal origin. Furthermore, no mutation was found in the coding regions of MKRN3 gene.

An informed written consent was obtained from the patient and his parents to perform the genetic analyses and to accept the publication of the data in this article.

Literature analysis and discussion

We collected and analyzed clinical and hormonal data in our case and 7 other cases of ICPP in KS reported in the literature [9–14]. The clinical and biological data at definitive puberty in each case were also considered. The characteristics of the 8 cases of ICPP in KS are summarized in Table 2. We also compared the hormonal profile between ICPP patients with KS (8 cases) and those with a normal karyotype reported in the literature (the most comprehensive cohort is published by Pigneur et al. [15]). Compared to patients with a normal karyotype (46,XY), KS patients have significantly higher LH and FSH levels during precocious puberty (KS + ICPP vs normal karyotype+ICPP: LH levels 9.4 ± 12 vs 1.1 ± 0.6 UI/l; FSH levels 23.1 ± 38.5 vs 2.7 ± 1.5 UI/l). Moreover, the response to LHRH in KS patients is more drastic (KS + ICPP vs normal karyotype+ICPP: LH levels post-LHRH 58 ± 48 vs 15.5 ± 0.8 UI/; FSH levels post-LHRH: 49.1 ± 62.1 vs 5.7 ± 3.9 UI/l) (Table 3). Even higher basal- and stimulated- LH and FSH levels during ICPP were noted in a KS patient with 48, XXYY karyotype [12] compared to boys with either normal karyotype [15] or 47,XXY (7 patients) (Table 2).

Table 2.

Analysis of characteristics of Klinefelter patients with ICPP

Characteristics during precocious puberty Final puberty-adulthood
Studies Karyotype Age at PP LH LH
post LHRH		 T TV Height (cm) LH FSH T TV
Leon et al. [9]

Mosaic XY/

XXY/XXXY

 8 – – – – 173 – – – –
Mühlendahl et al. [10] 47,XXY 8.3 6.3 42 3 3.4 181 – – – 3
Mühlendahl et al. [10] 47,XXY 8 – – 1.1 5 189 15 39 0.1 8
Bertelloni et al. [11] 47,XXY 5 4.2 37 2.8 4 176 16 13 2.9 4
Bertelloni et al. [12] 48,XXYY 7 31 130 4 – 176 45 130 4.2 –
Fryns et al. [13] 47,XXY – – – – – – – – – –
Gonzales-Ellis et al. [14] 47,XXY 8.5 1.9 – 0.86 – 164 3.5 – 2.7 4
Reported case 47,XXY 8 3.5 24 4.35 6 178 19 22 1.16 4
All (Mean ± SD) 7.5 ± 1.3 9 ± 12 58.2 ± 48 2.7 ± 1 4.6 ± 1 177 ± 7 20 ± 17 51 ± 61 2.2 ± 1.4 4.6 ± 1.7
Open in a new tab

FSH Follicle stimulating hormone, LH Luteinizing hormone, LHRH Luteinizing hormone-releasing hormone, PP Precocious puberty, T Testosterone levels, TV Testicular volume. Testosterone levels (T) are in ng/ml. TV corresponds to testicular volume in ml. LH and FSH are in UI/l.

Table 3.

Gonadotropin levels in patients with ICPP with a normal karyotype (adapted from Pigneur et al. [15]) and ICPP in cases with KS

LH
(UI/l)		 LH
Post-GnRH
(UI/l)		 FSH
(UI/l)		 FSH
Post-GnRH
(UI/l)		 T (ng/ml)
ICPP (Pigneur et al. 2008) (28 patients) (Mean ± SD)[15] 1.1 ± 0.6 15.5 ± 0.8 2.7 ± 1.5 5.7 ± 3.9 2.6 ± 2.1

ICPP+KS (8 cases) (5–9 years) (Mean ± SD)

Review of cases in the present study

 9.4 ± 12 58 ± 48 23.1 ± 38.5 49.1 ± 62.1 3.1 ± 1.3
Open in a new tab

ICPP Idiopathic central precocious puberty, KS Klinefelter syndrome, FSH Follicle stimulating hormone, LH Luteinizing hormone, GnRH Gonadotropin-releasing hormone, SD Standard deviation, T Testosterone levels. Data are presented as mean ± SD

In our patient, despite the precocious puberty, target height was attained. Similarly, in other reported cases of ICPP with KS, the height was attained in all patients, with (3 patients including our case) [9, 10] or without anti-androgen treatment (5 patients). This is explained by the potential role of short-stature homeobox gene (SHOX) overexpression in such patients due to their dysgonosomia compensating for an eventual short stature risk related to PP [16]. However, testosterone levels at mid-puberty (14–15 years) and the testicular volume in these ICPP patients are identical to the classical puberty profile of KS [17–20].

Indeed, around 450 boys with ICPP under the age of 9 years have been described in the published cohorts to date, accounting for about 8% of all central precocious puberty cases before the age of 9 year and 10% before the age of 10 years (Supplementary Table 1) [21–33]. The incidence of ICPP in boys is around 0.05/10,000 boys under the age of 9 years and 0.24/10,000 boys under the age of 10 years [32, 34, 35], while the incidence of KS is around 15/10,000 births [36]. Thus, the description of 8 cases of KS in around 450 reported cases of ICPP in the general population suggests an “overrepresentation” of ICPP in Klinefelter patients. The risk is estimated to be 1/370 KS patients by the Health Register of Belgium [13].

The unexpected “overrepresentation” of ICPP in KS raises two hypotheses. Firstly, while gonadotropin levels in KS patients during ICPP are as high as in 15 years old KS patients without ICPP, the testicular destruction is advanced [17, 37]. Higher gonadotropin levels during ICPP in KS patients compared to those in 46,XY patients suggest that a testicular factor could be a “peripheral initiator of GnRH pulsatility” during precocious puberty that is presumed to be central (ICPP). In KS patients, high estradiol levels is one of the earliest testicular anomalies [38]. Estrogen levels explain the chronological differences in puberty between girls and boys during puberty. Estrogen increases Kiss1 expression (gene coding kisspeptin, a major regulator of GnRH activation) in the hypothalamus during puberty. This effect is exerted through estrogen receptor (Erα). If this process is disrupted, puberty could be delayed [39]. Higher estradiol levels detected early in Klinefelter patients were proposed to precociously activate gonadotropin secretion [28, 31]. Indeed, it has been recently shown that estrogen promotes the expression of genes related to precocious puberty which activate GnRH secretion [40]. Germ cell apoptosis is another early phenomenon in KS [29]. The degree of germ cell apoptosis/seminiferous tissue fibrosis and Leydig cell dysfunction in KS are best reflected by FSH and LH levels respectively. Basal- and stimulated-LH and FSH levels are even higher in the patient with 48,XXYY [12]. This suggests that gonadotropin reserve correlates with the degree of testicular destruction, which is maximal in 48,XXYY patients. This hypothesis is also supported by the description of ICPP cases in patients with Turner syndrome and cryptorchidism [5, 41, 42]. Indeed, the testicular destruction and/or higher estrogen levels in Klinefelter patients would increase the hypothalamic/pituitary gonadotropin reserve and explain why these patients have higher basal and GnRH-stimulated LH and FSH levels during ICPP. These data are interesting and highlight the timing and role of testicular destruction in dysgonosomia to initiate GnRH pulsatility.

Secondly, in our patient, both X chromosomes were of maternal origin. None of the reported cases studied the origin of the supplementary X chromosome. It is worth noting that the supplementary X chromosome is equally inherited from paternal and maternal origin. When the origin of this supplementary X chromosome is maternal, it is hypothesized that some deleterious genes could escape the natural X chromosome inactivation [43, 44]. These deleterious genes could be responsible for an earlier activation of puberty in such patients [17, 45]. In line with this hypothesis, 2 X-linked gene mutations are described in the literature to be associated with ICPP in 2 boys: NR0B1 (responsible for X-linked adrenal hypoplasia congenita) [46] and MECP2 (responsible for Rett syndrome) [47]. On the contrary, paternal X chromosome (pX) is associated with further delayed puberty than those with a maternal X chromosome (mX) [17]. Puberty signs with significant increment in LH levels appeared respectively 1.9 and 1.3 years later in patients with pX. Additionally, androgen receptor (AR) gene is located on the X chromosome. It contains CAG repeats in the N terminal domain of exon 1 that could be highly polymorphic. The length of this repetition is inversely correlated with receptor activity [48], and is found to influence clinical presentation of KS [49]. Indeed, shorter CAG repeats and lower AR methylation were linked to premature pubarche [50]. Nevertheless, no study linked CAG repeats or AR activity to precocious puberty in KS patients.

Despite a number of interesting studies investigating early onset of puberty in patients with KS, the genetic basis of idiopathic central precocious puberty in both sexes remains elusive. Further studies using molecular genetics could help understanding the mechanisms of puberty initiation, timing and progression. Specifically, identifying novel X-linked genes in boys with precocious puberty will be instrumental to shed light on the mechanisms underlying puberty initiation.

Conclusions

ICPP is extremely rare in boys. ICPP patients with KS have higher gonadotropin levels than those with a normal karyotype. This suggests a peripheral or “testicular driver” that amplifies gonadotropin secretion through a positive feedback loop, which in turn triggers the initiation of central PP in such patients. Furthermore, maternal supplementary X chromosome in KS might play a role in the timing of puberty initiation. In boys with ICPP, long term endocrinological follow up until definitive puberty and karyotype analysis are important, specially if gonadotropin levels are significantly elevated or testicular volume is reduced.

Supplementary Information

Additional file 1. (138.3KB, docx)
12610_2020_117_MOESM2_ESM.docx (141.9KB, docx)

Additional file 2: Supplementary Table 1. Incidence of central precocious puberty (ICPP) according to sex. ICPP: Idiopathic central precocious puberty. CPP: Central precocious puberty. ICPP in boys accounts for 10% of the aetiologies of CPP. Data represent number of patients or percentage (%).

Acknowledgements

Not applicable.

Consent for participation

Patient’s written consent is obtained for genetic analyses and participation.

Abbreviations

AR

Androgen receptor

CNV

Copy number variations

CPP

Central precocious puberty

FSH

Follicle stimulating hormone

GnRH

Gonadotropin-releasing hormone

hCG

Human chorionic gonadotropin

ICPP

Idiopathic central precocious puberty

KS

Klinefelter syndrome

LH

Luteinizing hormone

LHRH

Luteinizing hormone-releasing hormone

MRI

Magnetic resonance imaging

mX

Maternal X chromosome

PCR

Polymerase chain reaction

PP

Precocious puberty

pX

Paternal X chromosome

SHOX

Short-stature homebox gene

UI

International units

Authors’ contributions

IT, FB, BB, MBL, AL and PT participated in the management of the patient and revised the manuscript, CPR and GS did the cytogenetic studies, KHMK edited the language and revised the manuscript, SM wrote and revised the manuscript. The author(s) read and approved the final manuscript.

Funding

The author(s) received no specific funding for this work.

Availability of data and materials

All the data concerning the case are made available in this manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Patient’s written consent is obtained for publication.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Carel J-C, Léger J. Clinical practice. Precocious puberty N Engl J Med. 2008;358:2366–2377. doi: 10.1056/NEJMcp0800459. [DOI] [PubMed] [Google Scholar]
  • 2.Partsch C-J, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol. 2002;56:129–148. doi: 10.1046/j.0300-0664.2001.01490.x. [DOI] [PubMed] [Google Scholar]
  • 3.Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005;116:1323–1328. doi: 10.1542/peds.2005-0012. [DOI] [PubMed] [Google Scholar]
  • 4.Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98:2198–2207. doi: 10.1210/jc.2013-1024. [DOI] [PubMed] [Google Scholar]
  • 5.Li L, Gong C. Central precocious puberty as a prelude of gonad dysplasia. Pediatr Investig. 2019;3:50–54. doi: 10.1002/ped4.12118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Improda N, Rezzuto M, Alfano S, Parenti G, Vajro P, Pignata C, et al. Precocious puberty in turner syndrome: report of a case and review of the literature. Ital J Pediatr. 2012;38:54. doi: 10.1186/1824-7288-38-54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Grosso S, Anichini C, Berardi R, Balestri P, Pucci L, Morgese G. Central precocious puberty and abnormal chromosomal patterns. Endocr Pathol. 2000;11:69–75. doi: 10.1385/EP:11:1:69. [DOI] [PubMed] [Google Scholar]
  • 8.Wikström AM, Dunkel L. Klinefelter syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25:239–250. doi: 10.1016/j.beem.2010.09.006. [DOI] [PubMed] [Google Scholar]
  • 9.Leon N, Wajchenberg BL, Beçak W. Precocious puberty in a case of Klinefelter’s syndrome. Acta Endocrinol. 1966;53:353–359. doi: 10.1530/acta.0.0530353. [DOI] [PubMed] [Google Scholar]
  • 10.von Mühlendahl KE, Heinrich U. Sexual precocity in Klinefelter syndrome: report on two new cases with idiopathic central precocious puberty. Eur J Pediatr. 1994;153:322–324. doi: 10.1007/BF01956410. [DOI] [PubMed] [Google Scholar]
  • 11.Bertelloni S, Baroncelli GI, Battini R, Saggese G. Central precocious puberty in Klinefelter syndrome: a case report with longitudinal follow-up of growth pattern. Am J Med Genet. 1996;65:52–55. doi: 10.1002/(SICI)1096-8628(19961002)65:1<52::AID-AJMG8>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  • 12.Bertelloni S, Battini R, Baroncelli GI, Guerrini R, Viacava P, Spinelli C, et al. Central precocious puberty in 48,XXYY Klinefelter syndrome variant. J Pediatr Endocrinol Metab JPEM. 1999;12:459–465. doi: 10.1515/JPEM.1999.12.3.459. [DOI] [PubMed] [Google Scholar]
  • 13.Fryns JP, Devriendt K. Precocious puberty in Klinefelter syndrome: non-specific result of neurological deficit? Am J Med Genet. 1997;72:122. doi: 10.1002/(SICI)1096-8628(19971003)72:1<122::AID-AJMG26>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 14.Gonzales-Ellis BA, Pingul MM, Reddy S, Boney CM, Wajnrajch MP, Quintos JB. Growth hormone deficiency and central precocious puberty in Klinefelter syndrome: report of a case and review of KIGS database. J Pediatr Endocrinol Metab JPEM. 2013;26:361–364. doi: 10.1515/jpem-2012-0333. [DOI] [PubMed] [Google Scholar]
  • 15.Pigneur B, Trivin C, Brauner R. Idiopathic central precocious puberty in 28 boys. Med Sci Monit Int Med J Exp Clin Res. 2008;14:CR10–CR14. [PubMed] [Google Scholar]
  • 16.Munns CJF, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89:4130–4135. doi: 10.1210/jc.2003-032230. [DOI] [PubMed] [Google Scholar]
  • 17.Wikström AM, Painter JN, Raivio T, Aittomäki K, Dunkel L. Genetic features of the X chromosome affect pubertal development and testicular degeneration in adolescent boys with Klinefelter syndrome. Clin Endocrinol. 2006;65:92–97. doi: 10.1111/j.1365-2265.2006.02554.x. [DOI] [PubMed] [Google Scholar]
  • 18.Wikström AM, Dunkel L, Wickman S, Norjavaara E, Ankarberg-Lindgren C, Raivio T. Are adolescent boys with Klinefelter syndrome androgen deficient? A longitudinal study of Finnish 47. XXY boys Pediatr Res. 2006;59:854–859. doi: 10.1203/01.pdr.0000219386.31398.c3. [DOI] [PubMed] [Google Scholar]
  • 19.Aksglæde L, Skakkebæk NE, Almstrup K, Juul A. Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. Acta Paediatr. 2011;100:793–806. doi: 10.1111/j.1651-2227.2011.02246.x. [DOI] [PubMed] [Google Scholar]
  • 20.Pacenza N, Pasqualini T, Gottlieb S, Knoblovits P, Costanzo PR, Stewart Usher J, et al. Clinical presentation of Klinefelter’s syndrome: differences according to age. Int J Endocrinol. 2012;2012:324835. doi: 10.1155/2012/324835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Schoevaart CE, Drop SL, Otten BJ, Slijper FM, Degenhart HJ. Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm Res. 1990;34:197–203. doi: 10.1159/000181825. [DOI] [PubMed] [Google Scholar]
  • 22.Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108:47–54. doi: 10.1016/S0022-3476(86)80767-3. [DOI] [PubMed] [Google Scholar]
  • 23.Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86:4711–4716. doi: 10.1210/jcem.86.10.7915. [DOI] [PubMed] [Google Scholar]
  • 24.Lebrethon MC, Bourguignon JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr. 2000;12:394–399. doi: 10.1097/00008480-200008000-00020. [DOI] [PubMed] [Google Scholar]
  • 25.Jaruratanasirikul S, Thaiwong M. Etiologies of precocious puberty: 15-year experience in a tertiary hospital in southern Thailand. J Pediatr Endocrinol Metab JPEM. 2010;23:1263–1271. doi: 10.1515/jpem.2010.200. [DOI] [PubMed] [Google Scholar]
  • 26.De Sanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, Galluzzi F, et al. Etiology of central precocious puberty in males: the results of the Italian study Group for Physiopathology of puberty. J Pediatr Endocrinol Metab JPEM. 2000;13(Suppl 1):687–693. doi: 10.1515/jpem.2000.13.s1.687. [DOI] [PubMed] [Google Scholar]
  • 27.Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central precocious puberty: clinical and laboratory features. Clin Endocrinol. 2001;54:289–294. doi: 10.1046/j.1365-2265.2001.01229.x. [DOI] [PubMed] [Google Scholar]
  • 28.Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res. 2002;58:1–7. doi: 10.1159/000065978. [DOI] [PubMed] [Google Scholar]
  • 29.Bajpai A, Sharma J, Kabra M, Kumar Gupta A, Menon PSN. Precocious puberty: clinical and endocrine profile and factors indicating neurogenic precocity in Indian children. J Pediatr Endocrinol Metab JPEM. 2002;15:1173–1181. doi: 10.1515/jpem.2002.15.8.1173. [DOI] [PubMed] [Google Scholar]
  • 30.Shiva S, Fayyazi A, Melikian A, Shiva S. Causes and types of precocious puberty in north-West Iran. Iran J Pediatr. 2012;22:487–492. [PMC free article] [PubMed] [Google Scholar]
  • 31.Soriano-Guillén L, Corripio R, Labarta JI, Cañete R, Castro-Feijóo L, Espino R, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95:4305–4313. doi: 10.1210/jc.2010-1025. [DOI] [PubMed] [Google Scholar]
  • 32.Le Moal J, Rigou A, Le Tertre A, De Crouy-Channel P, Léger J, Carel J-C. Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France. Eur J Endocrinol. 2018;178:33–41. doi: 10.1530/EJE-17-0379. [DOI] [PubMed] [Google Scholar]
  • 33.Alikasifoglu A, Vuralli D, Gonc EN, Ozon A, Kandemir N. Changing etiological trends in male precocious puberty: evaluation of 100 cases with central precocious puberty over the last decade. Horm Res Paediatr. 2015;83:340–344. doi: 10.1159/000377678. [DOI] [PubMed] [Google Scholar]
  • 34.Merke DP, Cutler GB. Evaluation and management of precocious puberty. Arch Dis Child. 1996;75:269–271. doi: 10.1136/adc.75.4.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, et al. Incidence and prevalence of central precocious puberty in Korea: an epidemiologic study based on a National Database. J Pediatr. 2019;208:221–228. doi: 10.1016/j.jpeds.2018.12.022. [DOI] [PubMed] [Google Scholar]
  • 36.Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus. Denmark Hum Genet. 1991;87:81–83. doi: 10.1007/BF01213097. [DOI] [PubMed] [Google Scholar]
  • 37.Wikström AM, Dunkel L. Testicular function in Klinefelter syndrome. Horm Res. 2008;69:317–326. doi: 10.1159/000117387. [DOI] [PubMed] [Google Scholar]
  • 38.Maqdasy S, Bogenmann L, Batisse-Lignier M, Roche B, Franck F, Desbiez F, et al. Leydig cell tumor in a patient with 49 XXXXY karyotype: a review of literature. Reprod Biol Endocrinol RBE. 2015;13:72. doi: 10.1186/s12958-015-0071-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Clarkson J, Boon WC, Simpson ER, Herbison AE. Postnatal development of an estradiol-kisspeptin positive feedback mechanism implicated in puberty onset. Endocrinology. 2009;150:3214–3220. doi: 10.1210/en.2008-1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Qian F, Shi N, Zhou H. Estrogen can promote the expression of genes related to precocious puberty in GT1-7 mouse hypothalamic GnRH neuronal cell line via activating G protein-coupled estrogen receptor. Gen Physiol Biophys. 2020;39:27–36. doi: 10.4149/gpb_2019049. [DOI] [PubMed] [Google Scholar]
  • 41.Pajno R, Pacillo L, Recupero S, Cicalese MP, Ferrua F, Barzaghi F, et al. Urogenital abnormalities in adenosine Deaminase deficiency. J Clin Immunol. 2020;40:610–618. doi: 10.1007/s10875-020-00777-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Monai E, Johansen A, Clasen-Linde E, Rajpert-De Meyts E, Skakkebæk NE, Main KM, et al. Central precocious puberty in two boys with Prader-Willi syndrome on growth hormone treatment. AACE Clin Case Rep. 2019;5:e352–e356. doi: 10.4158/ACCR-2019-0245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Iitsuka Y, Bock A, Nguyen DD, Samango-Sprouse CA, Simpson JL, Bischoff FZ. Evidence of skewed X-chromosome inactivation in 47,XXY and 48,XXYY Klinefelter patients. Am J Med Genet. 2001;98:25–31. doi: 10.1002/1096-8628(20010101)98:1<25::AID-AJMG1015>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 44.Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400–404. doi: 10.1038/nature03479. [DOI] [PubMed] [Google Scholar]
  • 45.Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL. Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome. J Clin Endocrinol Metab. 2005;90:5041–5046. doi: 10.1210/jc.2005-0432. [DOI] [PubMed] [Google Scholar]
  • 46.Shima H, Yatsuga S, Nakamura A, Sano S, Sasaki T, Katsumata N, et al. NR0B1 Frameshift mutation in a boy with idiopathic central precocious puberty. Sex Dev Genet Mol Biol Evol Endocrinol Embryol Pathol Sex Determ Differ. 2016;10:205–209. doi: 10.1159/000448726. [DOI] [PubMed] [Google Scholar]
  • 47.Tsuji-Hosokawa A, Matsuda N, Kurosawa K, Kashimada K, Morio T. A case of MECP2 duplication syndrome with gonadotropin-dependent precocious puberty. Horm Res Paediatr. 2017;87:271–276. doi: 10.1159/000449222. [DOI] [PubMed] [Google Scholar]
  • 48.Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003;26:76–83. doi: 10.1046/j.1365-2605.2003.00393.x. [DOI] [PubMed] [Google Scholar]
  • 49.Chang S, Skakkebæk A, Trolle C, Bojesen A, Hertz JM, Cohen A, et al. Anthropometry in Klinefelter syndrome--multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism. J Clin Endocrinol Metab. 2015;100:E508–E517. doi: 10.1210/jc.2014-2834. [DOI] [PubMed] [Google Scholar]
  • 50.Vottero A, Capelletti M, Giuliodori S, Viani I, Ziveri M, Neri TM, et al. Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? J Clin Endocrinol Metab. 2006;91:968–972. doi: 10.1210/jc.2005-2354. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1. (138.3KB, docx)
12610_2020_117_MOESM2_ESM.docx (141.9KB, docx)

Additional file 2: Supplementary Table 1. Incidence of central precocious puberty (ICPP) according to sex. ICPP: Idiopathic central precocious puberty. CPP: Central precocious puberty. ICPP in boys accounts for 10% of the aetiologies of CPP. Data represent number of patients or percentage (%).

Data Availability Statement

All the data concerning the case are made available in this manuscript.

Articles from Basic and Clinical Andrology are provided here courtesy of BMC

RESOURCES